The new COVID variant JN.1 is increasing the number of infections, but data indicates that upper respiratory tract symptoms account for the majority of symptoms. Former Chief of AIIMS, Dr. Randeep Guleria, stated
Covid-19 subvariant Dr. Randeep Guleria, a former director of the All India Institute of Medical Sciences (AIIMS), has stated that JN.1 is not leading to serious infections or hospital stays. He claimed, however, that the Omicron subvariant is more transmissible, spreading more quickly, and steadily taking over as the dominant variant, according to news agency ANI.
More infections are being caused by JN.1, but data indicates that upper respiratory tract symptoms account for the majority of symptoms, according to Dr. Guleria. Fever, coughing, cold, sore throat, runny nose, and body aches are some of these symptoms.
Also read-Why Is The New COVID-19 Vaccine Not Being Given To Americans
Does JN.1 require a new vaccine?
Dr. Guleria said that India does not need a variant-specific vaccine, but one that covers several variants. SARS-CoV-2 has undergone multiple mutations, and JN.1 is an Omicron subvariant. Therefore, a vaccine made against Omicron will be effective against JN.1 too, he explained. According to Dr. Guleria, more data is required to understand the current immunity of the population and the level of protection conferred by previous COVID-19 vaccinations. Based on this, it can be decided if a new vaccine is required.
New vaccine
If a new vaccine is made, it must cover the current circulating strain and also be effective against future variants. Dr. Guleria said that we need to have data on how frequently the population must be vaccinated and what will be a good vaccine that will cover a broader range of variants that already exist and that may emerge in the future. Dr. NK Arora, Chief, Indian SARS-CoV-2 Genomics Consortium (INSACOG), has said that no additional vaccine dose is required against the JN.1 subvariant. According to an ANI report, he said prevention is needed for people aged 60 years and older, for people who are likely to have comorbidities, and for those who are on medications that suppress one’s immunity. These include cancer patients. Dr. Arora suggested that these people should take a precautionary vaccine if they have not received one yet.
Omicron sub variants
He also said that several Omicron sub-variants have been reported, but none of them have increased severity, and hence, there is no need to panic. In the last 24 hours, Kerala had the highest number of COVID-19 cases out of all states. Of a total of 423 cases, as many as 266 were reported from Kerala, according to data from the Union health ministry.
Variants
JN.1, which originated from BA.2.86, has been classified as a variant of interest. Current evidence shows that the overall risk posed by JN.1 is low, according to the World Health Organization (WHO). JN.1 was first detected in the United States in September 2023. According to the Centers for Disease Control and Prevention, JN.1 is currently the fastest-growing variant in the US and is projected to continue increasing as a proportion of SARS-CoV-2 genomic sequences. The only difference between BA.2.86 and JN.1 is that of a spike protein. The CDC speculates that the continued growth of the variant suggests that JN.1 is either more transmissible or better at evading immune systems.
Currently, there is no evidence that JN.1 presents an increased risk to public health compared to other variants, and there is also no indication of increased severity from JN.1. The CDC has warned that COVID-19 is likely to increase in January 2024, and hence, people can get the updated COVID-19 vaccine to ensure enhanced protection.
Also read-Tuberculosis : A Patient’s Guide To Tuberculosis And Its Symptoms
images source: Google
Disclaimer: The opinions and suggestions expressed in this article are solely those of the individual analysts. These are not the opinions of HNN. For more, please consult with your doctor
